# Immune Tolerance Induction Study

> **NCT00701701** · PHASE4 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 4 (actual)

## Conditions studied

- Pompe Disease
- Glycogen Storage Disease Type II (GSD-II)
- Glycogenesis 2 Acid Maltase Deficiency

## Interventions

- **BIOLOGICAL:** Myozyme® (alglucosidase alfa)
- **BIOLOGICAL:** Myozyme® (alglucosidase alfa)

## Key facts

- **NCT ID:** NCT00701701
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-14
- **Primary completion:** 2020-02-18
- **Final completion:** 2020-02-18
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study was conducted to fulfill a post marketing commitment (PMC 6). FDA acknowledged fulfillment of PMC.
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701701, "Immune Tolerance Induction Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00701701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*